CL2013003485A1 - Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes. - Google Patents
Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes.Info
- Publication number
- CL2013003485A1 CL2013003485A1 CL2013003485A CL2013003485A CL2013003485A1 CL 2013003485 A1 CL2013003485 A1 CL 2013003485A1 CL 2013003485 A CL2013003485 A CL 2013003485A CL 2013003485 A CL2013003485 A CL 2013003485A CL 2013003485 A1 CL2013003485 A1 CL 2013003485A1
- Authority
- CL
- Chile
- Prior art keywords
- ilo
- disorders
- halogen
- disease
- piridin
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000013403 hyperactivity Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 150000001412 amines Chemical class 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical class N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 241001354404 Cyanus Species 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000009045 body homeostasis Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA EN LA QUE: RL ES HIDRÓGENO, HALÓGENO, CIANO, ALQUILO INFERIOR, ALQUILO INFERIOR SUSTITUIDO POR HALÓGENO, ALCOXI INFERIOR, ALCOXI INFERIOR SUSTITUIDO POR HALÓGENO O C(0)N1-12, O ES FENILO OPCIONALMENTE SUSTITUIDO POR HALÓGENO, CIANO O ALCOXI INFERIOR SUSTITUIDO POR HALÓGENO, O ES 2,2-DIFLUORBENZO[DL[1 ,3]DIOXOL-5-ILO, O ES 6-(TRIFLUORMETI-PIRAZIN-2-110 O 5-(TRIFLUORMETIL)PIRAZIN-2-ILO O ES 6-(TRIFLUORMETIL)PIRIMIDIN-4-ILO, O ES 6-(TRIFLUORMETIL)-PIRIDIN-3-ILO, O ES 5-CIANOPIRAZIN-2-ILO O ES 2-(TRI-FLUORMETIL)PIRIMIDIN-4-ILO; N ES EL NÚMERO 1 Ó 2 R2 ES HALÓGENO, ALQUILO INFERIOR O CIANO Y R3 ES HIDRÓGENO, O R2 ES HIDRÓGENO Y R3 ES HALÓGENO, ALQUILO INFERIOR O CIANO; X ES UN ENLACE, -NR'-, -CH2NH- O -CHR'-; R' ES HIDRÓGENO O ALQUILO INFERIOR; Z ES UN ENLACE, -CH2- U —O-; ARES FENILO O ES HETEROARILO ELEGIDO ENTRE EL GRUPO FORMADO POR 1H-INDAZOL-3-ILO, PIRIDIN-2-ILO, PIRIDIN-3-ILO, PIRIDIN-4-ILO, PIRIMIDIN-5-ILO, LH-PIRAZOL-3-ILO, LH-PIRAZOL-4-ILO Y 1H-PIRAZOL-5-ILO; O UNA SAL DE ADICIÓN DE ÁCIDO FARMACÉUTICAMENTE APROPIADA DE LOS MISMOS; COMPOSICIÓN FARMACÉUTICA; PROCEDIMIENTO DE PREPARACIÓN Y USO EN EL TRATAMIENTO DE LA DEPRESIÓN, LOS TRASTORNOS DE ANSIEDAD, EL TRASTORNO BIPOLAR, EL TRASTORNO DE HIPERACTIVIDAD CON DÉFICIT DE ATENCIÓN (ADHD), LOS TRASTORNOS RELACIONADOS CON EL ESTRÉS, LOS TRASTORNOS PSICÓTICOS, LA ESQUIZOFRENIA, LAS ENFERMEDADES NEUROLÓGICAS, LA ENFERMEDAD DE PARKINSON, LOS TRASTORNOS NEURODEGENERATIVOS, LA ENFERMEDAD DE ALZHEIMER, LA EPILEPSIA, LA MIGRAÑA, LA HIPERTENSIÓN, EL ABUSO DE SUSTANCIAS, LOS TRASTORNOS METABÓLICOS, LOS TRASTORNOS DE INGESTIÓN DE COMIDA, LA DIABETES, LAS COMPLICACIONES DIABÉTICAS, LA OBESIDAD, LA DISLIPIDEMIA, LOS TRASTORNOS DE CONSUMO Y ASIMILACIÓN DE ENERGÍA, LOS TRASTORNOS Y MALFUNCIÓN DE LA HOMEOSTASIS DE LA TEMPERATURA CORPORAL, LOS TRASTORNOS DEL SUEÑO Y DEL RITMO CIRCADIANO Y LOS TRASTORNOS CARDIOVASCULARES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169441 | 2011-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003485A1 true CL2013003485A1 (es) | 2014-09-12 |
Family
ID=46298391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003485A CL2013003485A1 (es) | 2011-06-10 | 2013-12-05 | Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9029370B2 (es) |
| EP (1) | EP2718271B1 (es) |
| JP (1) | JP5788087B2 (es) |
| KR (1) | KR101574906B1 (es) |
| CN (1) | CN103596937B (es) |
| AR (1) | AR086880A1 (es) |
| AU (1) | AU2012266462B2 (es) |
| BR (1) | BR112013030698B1 (es) |
| CA (1) | CA2834675C (es) |
| CL (1) | CL2013003485A1 (es) |
| CO (1) | CO6811866A2 (es) |
| CY (1) | CY1116769T1 (es) |
| DK (1) | DK2718271T3 (es) |
| EA (1) | EA022376B1 (es) |
| EC (1) | ECSP13013073A (es) |
| ES (1) | ES2546529T3 (es) |
| HK (1) | HK1192562A1 (es) |
| HR (1) | HRP20151201T1 (es) |
| IL (1) | IL229335A (es) |
| MA (1) | MA35194B1 (es) |
| MX (1) | MX354410B (es) |
| MY (1) | MY162461A (es) |
| PE (1) | PE20140968A1 (es) |
| PH (1) | PH12013502263A1 (es) |
| PL (1) | PL2718271T3 (es) |
| PT (1) | PT2718271E (es) |
| RS (1) | RS54415B1 (es) |
| SG (1) | SG194840A1 (es) |
| SI (1) | SI2718271T1 (es) |
| TW (1) | TWI445701B (es) |
| UA (1) | UA110388C2 (es) |
| WO (1) | WO2012168265A1 (es) |
| ZA (1) | ZA201308401B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| CA2856204A1 (en) * | 2012-01-12 | 2013-07-18 | F. Hoffmann-La Roche Ag | Heterocyclic derivatives as trace amine associated receptors (taars) |
| EP2895477B1 (en) * | 2012-09-14 | 2017-11-01 | F. Hoffmann-La Roche AG | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease. |
| BR112015001771B1 (pt) * | 2012-09-17 | 2022-08-16 | F. Hoffmann-La Roche Ag | Derivados de carboxamida de triazol, seu uso e composição farmacêutica que os compreende |
| WO2014072257A1 (en) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Pyrazine derivatives |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| EP3149002B1 (en) * | 2014-05-28 | 2018-04-25 | F.Hoffmann-La Roche Ag | 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators |
| CN104478798B (zh) * | 2014-12-18 | 2017-01-18 | 武汉华纳联合药业有限公司 | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 |
| WO2017157873A1 (en) | 2016-03-17 | 2017-09-21 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
| WO2021005137A1 (en) * | 2019-07-11 | 2021-01-14 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted pyrazole derivatives |
| CN115515940A (zh) * | 2020-02-28 | 2022-12-23 | 德州大学系统董事会 | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 |
| WO2024118488A1 (en) * | 2022-11-28 | 2024-06-06 | Sumitomo Pharma America, Inc. | 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| RU2235092C2 (ru) | 1997-12-04 | 2004-08-27 | Оллерган Инк. | Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| WO2008026046A1 (en) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
| CL2007003874A1 (es) * | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| BRPI0806932A2 (pt) | 2007-02-02 | 2014-05-06 | Novartis Ag | Antagonista do receptor s1p1 de cromeno |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| EP2182935A1 (en) | 2007-08-02 | 2010-05-12 | F. Hoffmann-Roche AG | The use of benzamide derivatives for the treatment of cns disorders |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| CN102711473B (zh) | 2009-09-04 | 2016-11-09 | 比奥根Ma公司 | 布鲁顿酪氨酸激酶抑制剂 |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
-
2012
- 2012-06-01 US US13/485,993 patent/US9029370B2/en active Active
- 2012-06-06 MX MX2013014371A patent/MX354410B/es active IP Right Grant
- 2012-06-06 PT PT127276335T patent/PT2718271E/pt unknown
- 2012-06-06 CN CN201280028534.4A patent/CN103596937B/zh active Active
- 2012-06-06 MY MYPI2013003963A patent/MY162461A/en unknown
- 2012-06-06 KR KR1020147000701A patent/KR101574906B1/ko active Active
- 2012-06-06 BR BR112013030698-0A patent/BR112013030698B1/pt not_active IP Right Cessation
- 2012-06-06 SG SG2013082656A patent/SG194840A1/en unknown
- 2012-06-06 DK DK12727633.5T patent/DK2718271T3/en active
- 2012-06-06 CA CA2834675A patent/CA2834675C/en active Active
- 2012-06-06 WO PCT/EP2012/060637 patent/WO2012168265A1/en active Application Filing
- 2012-06-06 JP JP2014514044A patent/JP5788087B2/ja active Active
- 2012-06-06 PH PH1/2013/502263A patent/PH12013502263A1/en unknown
- 2012-06-06 PE PE2013002778A patent/PE20140968A1/es active IP Right Grant
- 2012-06-06 AU AU2012266462A patent/AU2012266462B2/en not_active Ceased
- 2012-06-06 EA EA201391815A patent/EA022376B1/ru not_active IP Right Cessation
- 2012-06-06 EP EP12727633.5A patent/EP2718271B1/en active Active
- 2012-06-06 RS RS20150747A patent/RS54415B1/en unknown
- 2012-06-06 PL PL12727633T patent/PL2718271T3/pl unknown
- 2012-06-06 ES ES12727633.5T patent/ES2546529T3/es active Active
- 2012-06-06 SI SI201230320T patent/SI2718271T1/sl unknown
- 2012-06-06 UA UAA201400121A patent/UA110388C2/ru unknown
- 2012-06-07 TW TW101120551A patent/TWI445701B/zh active
- 2012-06-08 AR ARP120102045A patent/AR086880A1/es unknown
-
2013
- 2013-11-07 ZA ZA2013/08401A patent/ZA201308401B/en unknown
- 2013-11-07 IL IL229335A patent/IL229335A/en active IP Right Grant
- 2013-11-29 CO CO13281375A patent/CO6811866A2/es active IP Right Grant
- 2013-12-05 CL CL2013003485A patent/CL2013003485A1/es unknown
- 2013-12-10 EC ECSP13013073 patent/ECSP13013073A/es unknown
- 2013-12-18 MA MA36585A patent/MA35194B1/fr unknown
-
2014
- 2014-06-20 HK HK14105919.1A patent/HK1192562A1/zh not_active IP Right Cessation
-
2015
- 2015-10-06 CY CY20151100894T patent/CY1116769T1/el unknown
- 2015-11-09 HR HRP20151201TT patent/HRP20151201T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003485A1 (es) | Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes. | |
| ECSP13013072A (es) | Derivados de pirazol | |
| ECSP13012896A (es) | Derivados heterocíclicos de amina | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| CO6531470A2 (es) | Derivados benzamida sustituidos | |
| CO6321133A2 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns | |
| BR112012011105A2 (pt) | derivados de oxazolina para tratamento de doenças do snc | |
| CO7350619A2 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| MY168937A (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| BR112014015832A2 (pt) | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) | |
| ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
| BR112017000160A2 (pt) | derivados de azetidina substituidos como ligantes de taar | |
| EA201590454A1 (ru) | Производные пиразолкарбоксамида в качестве модуляторов рецепторов следовых аминов (taar) для применения при лечении различных расстройств, таких как депрессия, диабет и болезнь паркинсона | |
| BR112015001771A2 (pt) | derivados de carboxamida de triazol | |
| UA104152C2 (ru) | Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии | |
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). | |
| PH12015500346A1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| BR112015009990A2 (pt) | derivados de pirazina | |
| CY1110087T1 (el) | Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο | |
| DE602008006720D1 (de) | Neue disubstituierte phenylpyrrolidine als modulatoren der kortikalen katecholaminergen neurotransmission | |
| MX2011008178A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3). | |
| AR063811A1 (es) | 4-imidazoles sustituidos | |
| MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 |